We are a team of scientific, medical, financial, technological, and operational leaders built to serve our partners
Our deep understanding of subsector-specific scientific, regulatory, and commercial dynamics underpins everything we do.
Raymond F. Schinazi, PhD, DSc
Advisor
+
Raymond F. Schinazi, PhD, DSc
Advisor
Dr. Schinazi is widely considered one of the most prolific antiviral drug developers of all time and is responsible for the discovery and/or development of five drugs used to treat HIV, HBV and HCV. Dr. Schinazi is currently the Frances Winship Professor of Pediatrics, Director of the Laboratory of Biochemical Pharmacology, and Co-Director of the HIV Cure Scientific Working Group within the NIH-sponsored Emory University Center for AIDS Research. His laboratory develops approaches to treat infections caused by HIV, HBV, HCV, herpes, influenza, Zika, West Nile, chikungunya and dengue virus, among others. Insights from 40 years of research at Emory University led Dr. Schinazi to found multiple successful biotechnology companies, including Pharmasset, Inc. (VRUS; acquired by Gilead Sciences, Inc. for $11.4 billion in 2012), Idenix Pharmaceuticals, Inc. (IDIX; acquired by Merck & Co., Inc. for $3.9 billion in 2014) and Triangle Pharmaceuticals, Inc. (VIRS; acquired by Gilead Sciences, Inc. for $464 million in 2003). In 2014, Dr. Schinazi also led the merger of his namesake RFS Pharma, LLC with Cocrystal Pharma, Inc. (NASDAQ: COCP), where he served as Chairman of the Board. In addition to his work at Emory University, Dr. Schinazi spent 35 years at the Atlanta Department of Veterans Affairs (later receiving the VA Lab’s highest honor for his service). He is also Trustee for amfAR, The Foundation for AIDS Research, and served on the Boards of Global Virus Network, Inc., Brace Pharmaceuticals, Inc., Gliknik Inc., ReViral Pharmaceuticals Ltd., and Precision BioSciences, Inc.
Raymond F. Schinazi, PhD, DSc
Advisor
Dr. Schinazi is widely considered one of the most prolific antiviral drug developers of all time and is responsible for the discovery and/or development of five drugs used to treat HIV, HBV and HCV. Dr. Schinazi is currently the Frances Winship Professor of Pediatrics, Director of the Laboratory of Biochemical Pharmacology, and Co-Director of the HIV Cure Scientific Working Group within the NIH-sponsored Emory University Center for AIDS Research. His laboratory develops approaches to treat infections caused by HIV, HBV, HCV, herpes, influenza, Zika, West Nile, chikungunya and dengue virus, among others. Insights from 40 years of research at Emory University led Dr. Schinazi to found multiple successful biotechnology companies, including Pharmasset, Inc. (VRUS; acquired by Gilead Sciences, Inc. for $11.4 billion in 2012), Idenix Pharmaceuticals, Inc. (IDIX; acquired by Merck & Co., Inc. for $3.9 billion in 2014) and Triangle Pharmaceuticals, Inc. (VIRS; acquired by Gilead Sciences, Inc. for $464 million in 2003). In 2014, Dr. Schinazi also led the merger of his namesake RFS Pharma, LLC with Cocrystal Pharma, Inc. (NASDAQ: COCP), where he served as Chairman of the Board. In addition to his work at Emory University, Dr. Schinazi spent 35 years at the Atlanta Department of Veterans Affairs (later receiving the VA Lab’s highest honor for his service). He is also Trustee for amfAR, The Foundation for AIDS Research, and served on the Boards of Global Virus Network, Inc., Brace Pharmaceuticals, Inc., Gliknik Inc., ReViral Pharmaceuticals Ltd., and Precision BioSciences, Inc.